© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group. In intermediate-risk cytogenetic acute myeloid leukemia (IRC-AML) patients, novel biomarkers to guide post-remission therapy are needed. We analyzed with high-density arrays 40 IRC-AML patients who received a non-allogeneic hematopoietic stem-cell transplantation-based post-remission therapy, and identified a signature that correlated with early relapse. Subsequently, we analyzed selected 187 genes in 49 additional IRC-AML patients by RT-PCR. BAALC, MN1, SPARC and HOPX overexpression correlated to refractoriness. BAALC or ALDH2 overexpression correlated to shorter overall survival (OS) (5-year OS: 33 ± 8.6% vs. 73.7 ± 10.1%, p =.006; 32 ± 9.3% vs. 66.4 ± 9.7%, p =.016), whereas GPR44 or TP53INP1 overexpression correlated to longer survival (5-year OS: 66.7 ± 10.3% vs. 35.4 ± 9.1%, p =.04; 58.3 ± 8.2% vs. 23.1 ± 11.7%, p =.029). A risk-score combining these four genes expression distinguished low-risk and high-risk patients (5-year OS: 79 ± 9% vs. 30 ± 8%, respectively; p =.001) in our cohort and in an independent set of patients from a public repository. Our 4-gene signature may add prognostic information and guide post-remission treatment in IRC-AML patients.
|Journal||Leukemia and Lymphoma|
|Publication status||Published - 3 Oct 2018|
Torrebadell, M., Díaz-Beyá, M., Kalko, S. G., Pratcorona, M., Nomdedeu, J., Navarro, A., Gel, B., Brunet, S., Sierra, J., Camós, M., & Esteve, J. (2018). A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia. Leukemia and Lymphoma, 59, 2394-2404. https://doi.org/10.1080/10428194.2017.1422859